Clarity Pharmaceuticals (ASX:CU6), an Australia-based clinical-stage radiopharmaceutical company focused on developing next-generation products for cancer treatment, said on Thursday that it has entered into a supply agreement for copper-67 with US-based medical radioisotopes supplier Nusano Inc.

Nusano's 190,000 sq ft state-of-the-art facility in West Valley City, Utah is expected to begin operations in late 2025 with copper-67 isotope supply planned to commence in mid-2026. Clarity says that Nusano is uniquely positioned to regularly supply this therapeutic isotope for both Clarity's clinical trials and commercial use based on the ease of production and readily available target material. Nusano is setting up its own enriched stable isotope production for copper-67 starting materials soon, reducing supply chain risks while allowing for a fully integrated production process in the United States.

The copper-67 supply from Nusano further expands Clarity's growing network of US-based suppliers, which includes NorthStar Medical Radioisotopes LLC and Idaho State University Idaho Accelerator Center (IAC).

The new supply agreement is for an initial period of three years with automatic renewal for successive two-year periods.